KLRB1 and Miyoshi myopathy: AlloCAR-NKT cells could deploy CAR/TCR/NKR triple-targeting mechanisms, suitable for CD1d+ tumors, such as certain types of blood cancer (for example, MM, acute myeloid leukemia and myelomonocytic leukemia) and some solid tumors (for example, medulloblastoma and glioblastoma) (Fig. 2a)18.